Boehringer Ingelheim Advances Weight Loss Drug Development

Boehringer Ingelheim has made significant progress in the development of its weight loss injections, with new study results for Survodutid showing promise for regulatory approval. The article also mentions other business news like Eli Lilly's acquisition and China blocking an AI.

Post Share

Sources

Showing 0 of 1 sources

No articles available in your preferred languages.

1 article available in other languages below.

fazGerman1h ago

Survodutid: Studie zur Abnehmspritze lässt Boehringer „in Richtung Zulassung hoffen“

Das Mittel Survodutid soll nicht nur Menschen mit Adipositas, sondern auch Patienten mit schweren Lebererkrankungen helfen. Nun stellt Boehringer Ingelheim erste Ergebnisse vor.

Read full article →

PERSPECTA

PERSPECTA

Boehringer Ingelheim Advances Weight Loss Drug Development

Sources

Survodutid: Studie zur Abnehmspritze lässt Boehringer „in Richtung Zulassung hoffen“

Related Stories

Oil Jumps Above $100 After US-Iran Talks Fail

Philippines Leads Region in Pension Coverage, Viability Questioned

Pakistan's Finance Minister Projects 4% Economic Growth for FY26

Former Ghanaian Finance Minister's US Immigration Case Set for June 15, 2026

PERSPECTA